

Shinya Goto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5660262/publications.pdf>

Version: 2024-02-01

248
papers

29,128
citations

12303

69
h-index

5101

166
g-index

263
all docs

263
docs citations

263
times ranked

23066
citing authors

#	ARTICLE	IF	CITATIONS
1	GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 214-227.	1.8	19
2	The Future Role of High-Performance Computing in Cardiovascular Medicine and Science -Impact of Multi-Dimensional Data Analysis-. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 559-562.	0.9	5
3	Important Regulatory Roles of Erythrocytes in Platelet Adhesion to the von Willebrand Factor on the Wall under Blood Flow Conditions. <i>Thrombosis and Haemostasis</i> , 2022, 122, 974-983.	1.8	6
4	A Patient-Level Meta-Analysis: The End of the Era of Direct Oral Anticoagulant Developmental Trials in Patients With Atrial Fibrillation?. <i>Circulation</i> , 2022, 145, 256-258.	1.6	3
5	Contributing role of mitochondrial energy metabolism on platelet adhesion, activation and thrombus formation under blood flow conditions. <i>Platelets</i> , 2022, 33, 1083-1089.	1.1	3
6	Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 216-217.	1.4	1
7	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149
8	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
9	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
10	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	1.0	23
11	Computer Simulation of Platelet Adhesion around Stent Struts in the Presence and Absence of Tissue Defects around Them. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-8.	0.5	2
12	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021, 5, 1081-1091.	2.5	30
13	Safety of antithrombotic therapy in East Asian patients. <i>Internal and Emergency Medicine</i> , 2021, 16, 1443-1450.	1.0	7
14	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009614.	2.1	1
15	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, , .	1.9	8
16	Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. <i>Heart and Vessels</i> , 2020, 35, 170-176.	0.5	5
17	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020, 302, 53-58.	0.8	5
18	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. <i>International Journal of Stroke</i> , 2020, 15, 308-317.	2.9	12

#	ARTICLE	IF	CITATIONS
19	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	1.4	29
20	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020, 22, 195-204.	0.7	22
21	Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1425-1436.	1.2	88
22	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1012-1014.	1.1	5
23	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	2.8	28
24	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€”TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015785.	1.6	7
25	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	1.0	54
26	Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e200107.	2.8	22
27	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020, 191, 103-112.	0.8	22
28	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	0.9	34
29	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	1.0	50
30	Variability of PT-INR values measured by point of care devices INRatio/INRatio 2 and CoaguChek XS and standard laboratory method. A cross-sectional study. <i>Archives of Medical Science</i> , 2020, , .	0.4	1
31	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	1.8	34
32	Illustrated Stateâ€”ofâ€”theâ€”Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
33	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	0.6	8
34	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2019, 394, 1169-1180.	6.3	155
35	Global Trial or Local One?. <i>Circulation</i> , 2019, 140, 1878-1880.	1.6	5
36	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet</i> , The, 2019, 393, 407-415.	6.3	512

#	ARTICLE	IF	CITATIONS
37	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	1.9	30
38	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
39	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
40	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
41	Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition. <i>Thrombosis Research</i> , 2019, 179, 121-127.	0.8	8
42	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
43	Letter by Goto and Goto Regarding Article, "Fully Automated Echocardiogram Interpretation in Clinical Practice: Feasibility and Diagnostic Accuracy". <i>Circulation</i> , 2019, 139, 1646-1647.	1.6	2
44	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
45	Prediction of binding characteristics between von Willebrand factor and platelet glycoprotein Ib α with various mutations by molecular dynamic simulation. <i>Thrombosis Research</i> , 2019, 184, 129-135.	0.8	9
46	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
47	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019, 64, 166-179.	4.3	34
48	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
49	Artificial intelligence to predict needs for urgent revascularization from 12-lead electrocardiography in emergency patients. <i>PLoS ONE</i> , 2019, 14, e0210103.	1.1	62
50	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. <i>Ageing Research Reviews</i> , 2019, 49, 115-124.	5.0	34
51	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
52	Understanding of pathophysiology of thrombosis and prediction of the efficacy of medicine using simulation approach. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 856-861.	0.1	0
53	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	51
54	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	1.4	9

#	ARTICLE	IF	CITATIONS
55	Validation of DAPT Score (Dual Antiplatelet Therapy) in East Asian Patients. <i>Circulation</i> , 2018, 137, 563-566.	1.6	2
56	Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 857-864.	0.7	4
57	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan—Insights From GARFIELD-AF. <i>Circulation Journal</i> , 2018, 83, 67-74.	0.7	12
58	Multicenter investigation of the incidence of inferior vena cava filter fracture. <i>Japanese Journal of Radiology</i> , 2018, 36, 661-668.	1.0	6
59	High rate of death in patients with atrial fibrillation -Results from EORP-AF Pilot General Registry-. <i>International Journal of Cardiology</i> , 2018, 271, 109-110.	0.8	1
60	The diagnosis and treatment of venous thromboembolism in Asian patients. <i>Thrombosis Journal</i> , 2018, 16, 4.	0.9	65
61	Edoxaban's Journey. <i>Journal of the American College of Cardiology</i> , 2018, 72, 854-856.	1.2	0
62	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	1.1	80
63	Is there a "therapeutic window" for antiplatelet therapy?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 18-20.	1.4	1
64	Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Heart Rhythm</i> , 2017, 14, 599-605.	0.3	7
65	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 623-628.	1.2	54
66	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
67	EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 315.	1.2	0
68	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , 2017, 389, 1799-1808.	6.3	174
69	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clinical Cardiology</i> , 2017, 40, 932-939.	0.7	43
70	Does Computer Simulation Help Facilitate Personalized Precision Medicine for the Use of Warfarin?. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	1
71	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92
72	Platelet receptors as therapeutic targets: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1249-1257.	1.8	57

#	ARTICLE	IF	CITATIONS
73	Evidence-Based Carotid Interventions for Stroke Prevention: State-of-the-art Review. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 373-387.	0.9	32
74	A method and preliminary results of <i>in silico</i> computer simulation for the formation of mix thrombi with platelet and fibrin. <i>Journal of Biorheology</i> , 2017, 31, 30-34.	0.2	4
75	Prediction of Molecular Interaction between Platelet Glycoprotein Ib α and von Willebrand Factor using Molecular Dynamics Simulations. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 455-464.	0.9	21
76	Global Anticoagulant Registry in the Field “ Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	1.8	46
77	Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. <i>Journal of the American Heart Association</i> , 2016, 5, e002944.	1.6	37
78	Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. <i>Heart Rhythm</i> , 2016, 13, 2340-2347.	0.3	25
79	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
80	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
81	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016, 223, 543-547.	0.8	71
82	Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation “ Subgroup analysis of J-ROCKET AF. <i>Journal of Cardiology</i> , 2016, 68, 523-528.	0.8	13
83	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	1.0	8
84	Vascular Engineering of Blood Coagulation. , 2016, , 211-219.		2
85	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2 P -TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5
86	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
87	Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	7
88	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
89	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
90	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118

#	ARTICLE	IF	CITATIONS
91	What is the meaning of P2Y12 reaction units in patients with essential thrombocythemia?. <i>Journal of Cardiology Cases</i> , 2015, 12, 205-207.	0.2	0
92	Why do we need observational studies of everyday patients in the real-life setting?: Table A1. <i>European Heart Journal Supplements</i> , 2015, 17, D2-D8.	0.0	101
93	Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasis— Translation From Basic Science to Clinical Medicine. <i>Circulation Journal</i> , 2015, 79, 1871-1881.	0.7	26
94	Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome— Randomized, Double-Blind, Phase III PHILO Study. <i>Circulation Journal</i> , 2015, 79, 2452-2460.	0.7	218
95	How Can We Bridge the Results of Global Clinical Trials and Region/Country Specific Clinical Practice by Region/Country Specific Registry Data?. <i>Circulation Journal</i> , 2015, 79, 287-288.	0.7	1
96	Adhesive Forces between A1 Domain of von Willebrand Factor and N-terminus Domain of Glycoprotein I β Measured by Atomic Force Microscopy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1091-1099.	0.9	13
97	Acquired von Willebrand Syndrome (AVWS) as an Important Diagnostic Category of Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 231-232.	0.9	2
98	Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0133308.	1.1	39
99	Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events—Thrombolysis in Myocardial Infarction 50 (TRA-2P—TIMI50) Trial. <i>Circulation</i> , 2015, 131, 1041-1043.	1.6	9
100	Editorial Comment for the “Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials”, Thrombocytopenia as an important complication with the use of antithrombotic agents. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 29-30.	1.4	0
101	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	68
102	Interaction between diabetes and a high ankle-brachial index on mortality risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 615-621.	0.8	18
103	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74
104	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. <i>Circulation</i> , 2015, 132, 923-931.	1.6	397
105	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2015, 132, 624-632.	1.6	203
106	Editorial comment on “A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation”. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 83-85.	1.4	1
107	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
108	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table A1. <i>European Heart Journal Supplements</i> , 2015, 17, D42-D52.	0.0	4

#	ARTICLE	IF	CITATIONS
109	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	1.0	144
110	Development of Virtual Platelets Implementing the Functions of Three Platelet Membrane Proteins with Different Adhesive Characteristics. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 201-210.	0.9	19
111	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nature Reviews Cardiology</i> , 2014, 11, 597-606.	6.1	267
112	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 178-187.	0.7	20
113	New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2318-2326.	1.2	30
114	Platelet Repellent Properties of Hydrogel Coatings on Polyurethane-Coated Glass Surfaces. <i>ASAIO Journal</i> , 2014, 60, 587-593.	0.9	18
115	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1531-1540.	0.8	17
116	Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 1142-1147.	0.7	12
117	Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. <i>Journal of Gastroenterology</i> , 2014, 49, 814-824.	2.3	46
118	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>European Heart Journal</i> , 2014, 35, 1760-1768.	1.0	25
119	Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation in Relation to the CHADS2 Score: A Subgroup Analysis of the J-ROCKET AF Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 379-383.	0.7	15
120	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	0.8	64
121	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. <i>American Journal of Medicine</i> , 2014, 127, 53-60.e1.	0.6	43
122	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.	1.0	140
123	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. <i>European Heart Journal</i> , 2014, 35, 2864-2872.	1.0	238
124	Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. <i>Gut</i> , 2014, 63, 1061-1068.	6.1	49
125	Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. <i>Hypertension Research</i> , 2014, 37, 457-462.	1.5	10
126	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014, 168, 303-309.	1.2	128

#	ARTICLE	IF	CITATIONS
127	Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age. <i>Circulation Journal</i> , 2014, 78, 1349-1356.	0.7	56
128	Relationship between physiological function and metabolism of platelet cell. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2014, 25, 343-347.	0.1	0
129	A Modified Essen Stroke Risk Score for Predicting Recurrent Cardiovascular Events: Development and Validation. <i>International Journal of Stroke</i> , 2013, 8, 251-257.	2.9	17
130	Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 1317-1325.	0.7	26
131	Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis. <i>American Journal of Medicine</i> , 2013, 126, 693-700.e1.	0.6	121
132	Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice. <i>International Journal of Cardiology</i> , 2013, 167, 1380-1384.	0.8	8
133	Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. <i>Journal of the American College of Cardiology</i> , 2013, 62, 286-290.	1.2	88
134	Carotid Atherosclerosis and Risk of Subsequent Coronary Event in Outpatients With Atherothrombosis. <i>Stroke</i> , 2013, 44, 373-379.	1.0	65
135	Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke. <i>Stroke</i> , 2013, 44, 691-698.	1.0	89
136	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 730-738.	1.6	74
137	Unclassified Pleomorphic and Spindle Cell Pulmonary Neoplasm with Brain Metastases after Prasugrel. <i>Cardiology</i> , 2013, 124, 85-90.	0.6	8
138	Is the cause of gastric mucosal damage due only to aspirin use?. <i>Digestive Endoscopy</i> , 2013, 25, 214-215.	1.3	0
139	Antithrombotic Therapy for Prevention of Various Thrombotic Diseases. <i>Drug Development Research</i> , 2013, 74, 568-574.	1.4	12
140	Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry. <i>Clinical Cardiology</i> , 2013, 36, 721-727.	0.7	72
141	Randomized, Double-Blind Trial to Evaluate the Safety of Apixaban With Antiplatelet Therapy After Acute Coronary Syndrome in Japanese Patients (APPRAISE-J). <i>Circulation Journal</i> , 2013, 77, 2341-2348.	0.7	32
142	Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 632-638.	0.7	64
143	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	1.0	167
144	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. <i>PLoS ONE</i> , 2013, 8, e63479.	1.1	375

#	ARTICLE	IF	CITATIONS
145	High on-treatment platelet reactivity (HPR): What does it mean, and does it matter?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 177-178.	1.8	6
146	β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1340.	3.8	377
147	Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 241-249.	0.8	38
148	Monitoring of the Effects of New-Generation Oral Anticoagulants. <i>Circulation Journal</i> , 2012, 76, 596-597.	0.7	1
149	Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 2104-2111.	0.7	589
150	Burden of Nonsteroidal Anti-inflammatory and Antiplatelet Drug Use in Asia: A Multidisciplinary Working Party Report. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 753-760.	2.4	15
151	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	1.2	195
152	An International Model to Predict Recurrent Cardiovascular Disease. <i>American Journal of Medicine</i> , 2012, 125, 695-703.e1.	0.6	184
153	Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 318-324.	0.7	33
154	One-Year Atherothrombotic Vascular Events Rates in Outpatients with Recent Non-Cardioembolic Ischemic Stroke: The EVEREST (Effective Vascular Event REduction after STroke) Registry. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 245-253.	0.7	23
155	Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis. <i>Archives of Internal Medicine</i> , 2012, 172, 1086.	4.3	109
156	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
157	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 36-43.	1.0	16
158	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology</i> , The, 2012, 11, 503-511.	4.9	252
159	Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Mayo Clinic Proceedings</i> , 2011, 86, 960-967.	1.4	90
160	Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. <i>American Heart Journal</i> , 2011, 161, 815-821.e6.	1.2	88
161	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
162	Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion: An old question revisited. <i>Thrombosis and Haemostasis</i> , 2011, 106, 187-188.	1.8	1

#	ARTICLE	IF	CITATIONS
163	The role of trefoil factor family in apparently healthy subjects administered gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2011, 49, 136-140.	0.6	7
164	One-Year Cardiovascular Event Rates in Japanese Outpatients With Myocardial Infarction, Stroke, and Atrial Fibrillation. <i>Circulation Journal</i> , 2011, 75, 2598-2604.	0.7	32
165	Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 551-560.	1.3	10
166	Response to Letter Regarding Article, "Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries". <i>Circulation</i> , 2011, 123, .	1.6	0
167	Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease. <i>Circulation</i> , 2011, 123, 1854-1863.	1.6	124
168	Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2011, 123, 1843-1853.	1.6	147
169	Risk factors and outcomes for patients with vascular disease and serious bleeding events. <i>Heart</i> , 2011, 97, 1507-1512.	1.2	28
170	European physicians don't like cytoprotective agents?. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2011, 49, 67-67.	0.6	1
171	Sex-Related Differences in the Risk Factor Profile and Medications of Patients With Atrial Fibrillation Recruited in J-TRACE. <i>Circulation Journal</i> , 2010, 74, 650-654.	0.7	22
172	Basic Principles of Platelet Biology and Clinical Implications. <i>Circulation Journal</i> , 2010, 74, 597-607.	0.7	239
173	Is a "Pharmacogenomic Algorithm" Helpful for Adjusting the Initial Dose of Warfarin in Patients to Be Treated by Warfarin Therapy?. <i>Circulation Journal</i> , 2010, 74, 850-851.	0.7	1
174	Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 400-408.	1.5	37
175	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). <i>American Journal of Cardiology</i> , 2010, 105, 667-671.	0.7	60
176	Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 156-164.	0.9	106
177	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. <i>Archives of Internal Medicine</i> , 2010, 170, 1892.	4.3	319
178	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. <i>European Heart Journal</i> , 2010, 31, 227-235.	1.0	59
179	Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy. <i>Circulation</i> , 2010, 122, 1091-1100.	1.6	28
180	Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries. <i>Circulation</i> , 2010, 122, 1167-1175.	1.6	56

#	ARTICLE	IF	CITATIONS
181	Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1350.	3.8	626
182	Platelet thrombin receptor antagonism and atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 17-28.	1.0	214
183	Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1557-1567.	1.9	10
184	Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. <i>European Heart Journal</i> , 2010, 31, 2601-2613.	1.0	138
185	Risk Factor Profiles of Stroke, Myocardial Infarction, and Atrial Fibrillation: A Japanese Multicenter Cooperative Registry. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 190-197.	0.7	45
186	Lnk regulates integrin α IIb β 3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. <i>Journal of Clinical Investigation</i> , 2010, 120, 179-190.	3.9	84
187	Imaging of Structural Changes in Endothelial Cells and Thrombus Formation at the Site of FeCl ₃ -Induced Injuries in Mice Cremasteric Arteries. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 807-814.	0.9	23
188	Circadian Variations of Gastrointestinal Mucosal Damage Detected with Transnasal Endoscopy in Apparently Healthy Subjects Treated with Low-Dose Aspirin (ASA) for a Short Period. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 155-163.	0.9	21
189	Assessment of an ELISA Kit for Platelet-Derived Microparticles by Joint Research at Many Institutes in Japan. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 878-887.	0.9	52
190	Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. <i>European Heart Journal</i> , 2009, 30, 2318-2326.	1.0	277
191	Stroke Prevention by Cilostazol in Patients with Atherothrombosis: Meta-analysis of Placebo-controlled Randomized Trials. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 482-490.	0.7	66
192	Response to "Atrial fibrillation and atherothrombosis: The importance of anticoagulation" by Escobar C and Barrios V. <i>American Heart Journal</i> , 2009, 157, e29.	1.2	0
193	Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>American Heart Journal</i> , 2009, 158, 1038-1045.	1.2	36
194	Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: Results from 1-year outcomes in the Japanese REACH Registry. <i>Journal of the Neurological Sciences</i> , 2009, 287, 45-51.	0.3	53
195	ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions. <i>Atherosclerosis</i> , 2009, 203, 409-416.	0.4	30
196	Important Regulatory Role of Activated Platelet-Derived Procoagulant Activity in the Propagation of Thrombi Formed Under Arterial Blood Flow Conditions. <i>Circulation Journal</i> , 2009, 73, 540-548.	0.7	27
197	Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 607-609.	1.8	5
198	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. <i>American Heart Journal</i> , 2008, 156, 855-863.e2.	1.2	243

#	ARTICLE	IF	CITATIONS
199	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008, 29, 2202-2211.	1.0	183
200	Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells. <i>Journal of Experimental Medicine</i> , 2008, 205, 1917-1927.	4.2	62
201	Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. <i>Cerebrovascular Diseases</i> , 2008, 25, 366-374.	0.8	59
202	Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. <i>European Heart Journal</i> , 2008, 29, 3052-3060.	1.0	59
203	The challenge of monitoring platelet response after clopidogrel. <i>European Heart Journal</i> , 2008, 29, 2833-2834.	1.0	3
204	The Effect of Clearance Flow of Variable Area Nozzles on Radial Turbine Performance. , 2008, , .		15
205	The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE) A Nation-Wide, Prospective Large Cohort Study; The Study Design. <i>Circulation Journal</i> , 2008, 72, 991-997.	0.7	14
206	Cardiovascular risk factors in patients at high risk of atherothrombosis: What can be learned from registries?. <i>Thrombosis and Haemostasis</i> , 2008, 100, 611-613.	1.8	15
207	Antithrombotic therapy in heart disease. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 8-11.	0.1	0
208	Platelet Procoagulant Activity Appeared by Exposure of Platelets to Blood Flow Conditions. , 2008, , 290-297.		1
209	Blood constitution: platelet aggregation, bleeding, and involvement of leukocytes. <i>Reviews in Neurological Diseases</i> , 2008, 5 Suppl 1, S22-7.	0.3	1
210	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1197.	3.8	1,162
211	Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan Results From Domestic Baseline Data of the REduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Circulation Journal</i> , 2007, 71, 995-1003.	0.7	82
212	Are Japanese patients more prone to gastro-duodenal mucosal injury and bleeding with the use of antiplatelet agents?. <i>Thrombosis Research</i> , 2007, 120, 463-464.	0.8	4
213	Salvianolic Acid B Inhibits Hydrogen Peroxide-Induced Endothelial Cell Apoptosis through Regulating PI3K/Akt Signaling. <i>PLoS ONE</i> , 2007, 2, e1321.	1.1	76
214	235 mechanical properties of artificial platelet on the adhesive process. <i>The Proceedings of the Bioengineering Conference Annual Meeting of BED/JISME</i> , 2007, 2006.19, 294-295.	0.0	0
215	Dependence of Platelet Thrombus Stability on Sustained Glycoprotein IIb/IIIa Activation Through Adenosine 5'-Diphosphate Receptor Stimulation and Cyclic Calcium Signaling. <i>Journal of the American College of Cardiology</i> , 2006, 47, 155-162.	1.2	92
216	The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. <i>American Heart Journal</i> , 2006, 151, 786.e1-786.e10.	1.2	235

#	ARTICLE	IF	CITATIONS
217	Detection of von Willebrand Factor and Tissue Factor in Platelets-Fibrin Rich Coronary Thrombi in Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 97, 26-28.	0.7	51
218	Impact of Carotid Endarterectomy on Medical Secondary Prevention After a Stroke or a Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 2880-2885.	1.0	13
219	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 180.	3.8	1,353
220	Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. <i>Atherosclerosis Supplements</i> , 2005, 6, 3-11.	1.2	157
221	823 Artificial Platelet's transport and adhesion. The Proceedings of the JSME Annual Meeting, 2005, 2005.7, 49-50.	0.0	0
222	236 Influence of Artificial Platelet's Microscopic-motion to the adhesion. Proceedings of the JSME Bioengineering Conference and Seminar, 2005, 2004.17, 287-288.	0.0	0
223	Understanding the Mechanism of Platelet Thrombus Formation under Blood Flow Conditions and the Effect of New Antiplatelet Agents. <i>Current Vascular Pharmacology</i> , 2004, 2, 23-32.	0.8	27
224	Platelets, after Exposure to a High Shear Stress, Induce IL-10-Producing, Mature Dendritic Cells In Vitro. <i>Journal of Immunology</i> , 2004, 172, 5297-5303.	0.4	83
225	Propagation of Arterial Thrombi. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2207-2208.	1.1	21
226	Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. <i>Journal of the American College of Cardiology</i> , 2004, 44, 316-323.	1.2	83
227	Title is missing!. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2004, 15, 510-516.	0.1	2
228	Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. <i>Thrombosis Research</i> , 2003, 111, 357-361.	0.8	8
229	Application of Ex Vivo Flow Chamber System for Assessment of Stent Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1360-1364.	1.1	32
230	Involvement of Glycoprotein VI in Platelet Thrombus Formation on Both Collagen and von Willebrand Factor Surfaces Under Flow Conditions. <i>Circulation</i> , 2002, 106, 266-272.	1.6	123
231	Functional Significance of Adenosine 5'-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP I _b /III _a Induced by Conditions of High Shear Rate. <i>Circulation</i> , 2002, 105, 2531-2536.	1.6	124
232	Shear-induced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand. <i>Thrombosis Research</i> , 2002, 108, 311-315.	0.8	14
233	Specific Inhibiting Characteristics of Tetramethylpyrazine, One of the Active Ingredients of the Chinese Herbal Medicine "Chuanxiong," on Platelet Thrombus Formation Under High Shear Rates. <i>Thrombosis Research</i> , 2001, 104, 15-28.	0.8	57
234	Platelet Aggregability Under Shear is Enhanced in Patients With Unstable Angina Pectoris Who Developed Acute Myocardial Infarction. <i>Japanese Circulation Journal</i> , 2001, 65, 279-282.	1.0	5

#	ARTICLE	IF	CITATIONS
235	Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation. <i>Platelets</i> , 2001, 12, 406-414.	1.1	17
236	A New Approach to Antiplatelet Therapy: Inhibitor of GPIb/V/IX-vWF Interaction. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 44-52.	0.5	4
237	Plasma Concentration of von Willebrand Factor in Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2000, 84, 204-209.	1.8	70
238	Enhanced Shear-induced von Willebrand Factor Binding to Platelets in Acute Myocardial Infarction. <i>Thrombosis Research</i> , 2000, 100, 251-261.	0.8	16
239	Enhanced Shear-Induced Platelet Aggregation in Acute Myocardial Infarction. <i>Circulation</i> , 1999, 99, 608-613.	1.6	110
240	Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear. <i>Lancet, The</i> , 1999, 353, 809.	6.3	15
241	Platelet Spontaneous Aggregation in Platelet-Rich Plasma Is Increased in Habitual Smokers. <i>Thrombosis Research</i> , 1999, 93, 271-278.	0.8	125
242	Functional compensation of the low platelet count by increased individual platelet size in a patient with May-Hegglin anomaly presenting with acute myocardial infarction. <i>International Journal of Cardiology</i> , 1998, 64, 171-177.	0.8	16
243	Arterial thrombosis in heart failure. <i>Lancet, The</i> , 1998, 351, 1558-1559.	6.3	15
244	Von Willebrand Factor-Dependent Shear-Induced Platelet Aggregation: Basic Mechanisms and Clinical Implications. <i>Annals of the New York Academy of Sciences</i> , 1997, 811, 325-336.	1.8	49
245	SYNERGISTIC EFFECT OF EPINEPHRINE AND SHEARING ON PLATELET ACTIVATION. <i>Thrombosis Research</i> , 1996, 84, 351-359.	0.8	31
246	Conformational Changes in the A1 Domain of von Willebrand Factor Modulating the Interaction with Platelet Glycoprotein Ib. <i>Journal of Biological Chemistry</i> , 1996, 271, 9046-9053.	1.6	66
247	Characterization of the Unique Mechanism Mediating the Shear-dependent Binding of Soluble von Willebrand Factor to Platelets. <i>Journal of Biological Chemistry</i> , 1995, 270, 23352-23361.	1.6	251
248	Mechanism of Thrombus Formation in Regard to Diet. , 0, , .		0